Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Highlights: Nine subjects in cohort one intravenously dosed with RECCE® 327 at 50mg meets all endpoints, indicating to be safe and well toleratedIndependent Safety Committee clears second study...
-
Highlights: 10 healthy subjects recruited for Phase I clinical trialDosing in subjects will commence December 16, 2021RECCE® 327 (R327) may be the only clinical-stage anti-infective in development...
-
Highlights: Broad spectrum antibiotic activity on bacterial burn wound infections with visible infection reduction <24 hours on all patients to dateAll infections cleared within 5 days (acute)...
-
SYDNEY, Australia, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) (Company), the Company developing new classes of synthetic anti-infectives, today announced it will...
-
Highlights: Phase I clinical trial of RECCE® 327 approved to start intravenous ascending-dose, randomized, placebo-controlled, parallel, double-blind, single-dose studyAccording to Pew Charitable...
-
SYDNEY, Australia, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE) (FSE:R9Q) (Company), the Company developing new classes of synthetic anti-infectives, is pleased to announce...
-
SYDNEY, Australia, July 22, 2021 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q), the Company developing new classes of synthetic anti-infectives, is pleased to announce the United...
-
SYDNEY, Australia, July 21, 2021 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q), the Company developing new classes of synthetic anti-infectives, is pleased to announce the Chinese...
-
Highlights RECCE® 327 (R327) shown to reduce deadly ‘flesh-eating’ bacterial count Below Limit of Quantification (BLOQ) within 24 hours, at varying concentrationsR327 BLOQ efficacy as early as 30...
-
Highlights: Multiple patients dosed in Phase I/II clinical trial, an important human clinical milestoneNo adverse symptoms reported - R327 well stocked in hospital pharmacy for further patient...